AJ502 is a novel, potent, and selective PDE4 inhibitor that has good skin permeating characteristics.
Topically administered AJ502 showed efficacy in IMQ-induced psoriasis and PMA-induced atopic dermatitis in the animal models superior to that of marketed comparators. AJ502 is at IND-enabling stage.
- 60% 60%
- 40% 40%
- 30% 30%
- 15% 15%
- 10% 10%
We look forward to further discussions with you.
Please fill out the form, and we will get right back to you.